Travere Therapeutics (TVTX) Return on Capital Employed (2012 - 2026)
Travere Therapeutics' (TVTX) quarterly Return on Capital Employed came in at 12.55% in Q1 2026, up 4587.0% YoY from 0.27% in Q1 2025, and up 17.71% on a QoQ basis from 15.25% in Q4 2025.
Travere Therapeutics (TVTX) Return on Capital Employed (2012 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 15 years of Return on Capital Employed data on file, last reported at 12.55% in Q1 2026.
- Quarterly Return on Capital Employed rose 4587.0% year-over-year to 12.55% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 12.55% (up 4587.0% YoY) and the FY2025 annual result came in at 14.29%, up 5170.0% from the prior year.
- Return on Capital Employed advanced to 12.55% in Q1 2026, from 15.25% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 12.55% in Q1 2026 to a low of 105.8% in Q3 2024.
- A 5-year average of 54.65% and a median of 57.39% in 2022 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed sank 4681 bps — and 2025, when it jumped 8368 bps.
- Tracing TVTX's Return on Capital Employed over 5 years: stood at 57.39% in 2022, then dropped by 7 bps to 61.32% in 2023, then sank by 52 bps to 92.92% in 2024, then soared by 84 bps to 15.25% in 2025, then climbed by 18 bps to 12.55% in 2026.
- The last three Return on Capital Employed figures came in at 12.55% (Q1 2026), 15.25% (Q4 2025), and 22.13% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn | -7.70% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.70% |
| Mar 31, 2026 | -12.55% |
| Dec 31, 2025 | -15.25% |
| Sep 30, 2025 | -22.13% |
| Jun 30, 2025 | -47.50% |
| Mar 31, 2025 | -58.42% |
| Dec 31, 2024 | -92.92% |
| Sep 30, 2024 | -105.80% |
| Jun 30, 2024 | -81.01% |
| Mar 31, 2024 | -77.76% |
| Dec 31, 2023 | -61.32% |
| Sep 30, 2023 | -58.99% |
| Jun 30, 2023 | -58.22% |
| Mar 31, 2023 | -56.61% |
| Dec 31, 2022 | -57.39% |
| Sep 30, 2022 | -51.13% |
| Jun 30, 2022 | -39.31% |
| Mar 31, 2022 | -32.77% |
| Dec 31, 2021 | -30.60% |
| Sep 30, 2021 | -35.99% |